非一线核苷(酸)类似物经治慢性乙型肝炎患者治疗策略调整专家共识

中华医学会肝病学分会肝炎学组; 中华肝脏病杂志

doi:10.3969/j.issn.1001-5256.2019.06.008

非一线核苷(酸)类似物经治慢性乙型肝炎患者治疗策略调整专家共识

DOI: 10.3969/j.issn.1001-5256.2019.06.008

基金项目:

艾滋病和病毒性肝炎等重大传染病防治专项(2017ZX10201201、2017ZX10202202)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 309
- HTML全文浏览量: 48
- PDF下载量: 211
- 被引次数: 0
出版历程
- 出版日期: 2019-06-20

An expert consensus for the adjustment of treatment strategies in patients with chronic hepatitis B treated with non-first-line nucleos (t) ide analogues

Research funding:

摘要

摘要:
口服核苷(酸)类似物(NAs)抗病毒治疗是治疗慢性乙型肝炎(CHB)重要和有效的方法之一。从抗病毒作用强弱及耐药方面考虑,国内外指南将NAs类药物分为一线和非一线用药。《非一线核苷(酸)类似物经治慢性乙型肝炎患者治疗策略调整专家共识》主要针对目前正在使用非一线NAs类药物且有效的患者,如何规范地调整为一线NAs类药物,并强化CHB初始抗病毒治疗必须选择一线NAs类药物,使患者既可以获得更好的抗病毒疗效,提高患者的依从性,同时又可避免药物严重不良反应的发生。
- 肝炎,乙型,慢性 /
- 核苷(酸)类似物 /
- 经治 /
- 治疗策略 /
- 共识
Abstract:
Oral nucleos (t) ide analogues (NAs) is one of the main and efficient way for the treatment of chronic hepatitis B (CHB) . Considering the antiviral potency and drug resistance of domestic and foreign guidelines, NAs are divided into first-line and non-first-line drugs. “An Expert Consensus for the Adjustment of Treatment Strategies in Patients with Chronic Hepatitis B Treated with Non-first-line Nucleos (t) ide Analogues, ”is mainly aimed at those patients who are currently using non-first-line NAs drugs. In addition, how to standardize the adjustment to first-line NAs drugs of choice, which can strengthen the effectiveness of initial antiviral treatment to obtain better antiviral efficacy, and improve patient compliance, coinciding with the avoidance of occurrence of serious drug adverse reactions in patients with CHB is presented.
- hepatitis B, chronic /
- nucleos (t) ide analogues /
- treatment experienced /
- treatment strategy /
- consensus

HTML全文

参考文献(12)

[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[2]European Association for the Study of the Liver.EASL 2017clinical practice guidelines on the management of hepatitis Bvirus infection[J].J Hepatol, 2017, 67 (2) :370-398.

[3] TERRAULT NA, LOK AS, McMAHON BJ, et al.Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD2018 hepatitis B guidance[J].Hepatology, 2018, 67 (4) :1560-1599.

[4]World Health Organization.Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[M].Geneva:World Health Organization, 2015.

[5]YU R, FAN R, HOU JL.Chronic hepatitis B virus infection:Epidemiology, prevention, and treatment in China[J].Front Med, 2014, 8 (2) :135-144.

[6]LOK AS, TRINH H, CAROSI G, et al.Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos (t) ide-na6ve patients with chronic hepatitis B[J].Gastroenterology, 2012, 143 (3) :619-628.e1.

[7]AGARWAL K, BRUNETTO M, SETO WK, et al.96 weeks treatment of tenofovir alafenamide vs.tenofovir disoproxil fumarate for hepatitis B virus infection[J].J Hepatol, 2018, 68 (4) :672-681.

[8]BRUNETTO M, LIM YS, GANE E, et al.A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBe Ag-negative, chronic hepatitis B (CHB) :Efficacy and safety results at week 96[J].JHepatol, 2017, 66 (Suppl 1) :s25-s26.

[9]GU EL, YU YQ, WANG JL, et al.Response-guided treatment of cirrhotic chronic hepatitis B patients:Multicenter prospective study[J].World J Gastroenterol, 2015, 21 (2) :653-660.

[10]CHOI J, KIM H J, LEE J, et al.Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B:A Korean nationwide cohort study[J].JAMA Oncol, 2019, 5 (1) :30-36.

[11]FASANO M, LAMPERTICO P, MARZANO A, et al.HBV DNAsuppression and HBsAg clearance in HBe Ag negative chronic hepatitis B patients on lamivudine therapy for over 5 years[J].J Hepatol, 2012, 56 (6) :1254-1258.

[12]YU Y, WANG J, LI G, et al.Nucleos (t) ide analogue interruption:Alternative approach to intrahepatic set point for spontaneous control of HBV replication?[J].J Hepatol, 2018, 68 (3) :609-610.

施引文献

资源附件(0)

访问统计